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Summary
Background Human African trypanosomiasis (HAT; sleeping sickness) caused by Trypanosoma brucei gambiense is a 
fatal disease. Current treatment options for patients with second-stage disease are toxic, ineﬀ  ective, or impractical. 
We assessed the eﬃ   cacy and safety of nifurtimox-eﬂ  ornithine combination therapy (NECT) for second-stage disease 
compared with the standard eﬂ  ornithine regimen.
Methods A multicentre, randomised, open-label, active control, phase III, non-inferiority trial was done at four HAT 
treatment centres in the Republic of the Congo and the Democratic Republic of the Congo. Patients aged 15 years or 
older with conﬁ  rmed  second-stage  T b gambiense infection were randomly assigned by computer-generated 
randomisation sequence to receive intravenous eﬂ  ornithine (400 mg/kg per day, every 6 h; n=144) for 14 days or 
intravenous eﬂ  ornithine (400 mg/kg per day, every 12 h) for 7 days with oral nifurtimox (15 mg/kg per day, every 8 h) 
for 10 days (NECT; n=143). The primary endpoint was cure (deﬁ  ned as absence of trypanosomes in body ﬂ  uids and a 
leucocyte count ≤20 cells per μL) 18 months after treatment. Eﬃ   cacy analyses were done in the intention-to-treat 
(ITT), modiﬁ  ed ITT, and per-protocol (PP) populations. The non-inferiority margin for the diﬀ  erence in cure rates 
was deﬁ  ned as 10%. This study is registered with ClinicalTrials.gov, number NCT00146627. 
Findings One patient from the eﬂ  ornithine group absconded after receiving the ﬁ  rst dose, without any type of 
assessment done, and was excluded from all analyses. In the ITT population, 131 (91·6%) of 143 patients assigned to 
eﬂ  ornithine and 138 (96·5%) of 143 patients assigned to NECT were cured at 18 months (diﬀ  erence –4·9%, one-sided 
95% CI –0·3; p<0·0001). In the PP population, 122 (91·7%) of 133 patients in the eﬂ  ornithine group and 129 (97·7%) 
of 132 in the NECT group were cured at 18 months (diﬀ  erence –6·0%, one-sided 95% CI –1·5; p<0·0001). Drug-
related adverse events were frequent in both groups; 41 (28·7%) patients in the eﬂ  ornithine group and 20 (14·0%) in 
the NECT group had major (grade 3 or 4) reactions, which resulted in temporary treatment interruption in nine and 
one patients, respectively. The most common major adverse events were fever (n=18), seizures (n=6), and infections 
(n=5) in the eﬂ  ornithine group, and fever (n=7), seizures (n=6), and confusion (n=2) in the NECT group. There were 
four deaths, which were regarded as related to study drug (eﬂ  ornithine, n=3; NECT, n=1). 
Interpretation The eﬃ   cacy of NECT is non-inferior to that of eﬂ  ornithine monotherapy. Since this combination 
treatment also presents safety advantages, is easier to administer (ie, infusion every 12 h for 7 days vs every 
6 h for 14 days), and potentially protective against the emergence of resistant parasites, it is suitable for ﬁ  rst-line use 
in HAT control programmes.
Funding Médecins Sans Frontières (Dutch section), Médecins Sans Frontières International, and the Drugs for 
Neglected Diseases Initiative.
Introduction
Human African trypanosomiasis (HAT; sleeping 
sickness) is fatal without appropriate treatment. About 
12 000 cases of the disease are reported every year in sub-
Saharan Africa,
1 but the actual number of cases could be 
ﬁ   ve times higher. HAT is caused by the protozoan 
parasites Trypanosoma brucei gambiense (west and central 
Africa) and Trypanosoma brucei rhodesiense (east and 
southern Africa), and transmitted by the tsetse ﬂ  y. The 
disease progresses from a haemolymphatic ﬁ  rst stage to 
a meningoencephalitic second stage. Since 1949, the 
mainstay of treatment for second-stage HAT has been 
melarsoprol. This arsenical derivative causes severe 
adverse reactions, in particular reactive encephalopathy, 
which aﬀ  ects 5–10% of treated patients, and is fatal in 
10–70% of cases.
2 Moreover, increasing melarsoprol 
failure rates have been reported in several sites.
3–7
Eﬂ  ornithine (α-diﬂ  uoromethylornithine or DFMO) is the 
only new treatment registered for HAT in the past six 
decades. A trypanostatic drug, eﬂ  ornithine acts by suicide 
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inactivation of ornithine decarboxylase, an enzyme essential 
for polyamine synthesis that is needed for cell multiplication 
and diﬀ  erentiation.
8–10 Eﬂ  ornithine has proved eﬃ   cacious 
and better tolerated than melarsoprol, and most toxic 
eﬀ  ects—mainly seizures, gastrointestinal disorders, and 
myelosuppression—are reversible if well managed. 
However, the drug is diﬃ   cult to administer, requiring one 
slow infusion every 6 h for 14 days (56 infusions in total) 
because of its short half-life (1·5–5·0 h).
11,12 Eﬃ   cacy of a 
7-day regimen proved insuﬃ   cient.
13 Despite eﬂ  ornithine 
being available for free, the diﬃ   culty in administering it in 
resource-poor settings explains why melarsoprol remains 
the treatment of choice.
Nifurtimox is an orally administered drug used to treat 
American trypanosomiasis (Chagas disease, caused by 
Trypanosoma cruzi). Although not registered for the 
treatment of HAT, nifurtimox has been assessed in 
several case series and has shown varying eﬃ   cacy.
14–17 It is 
mainly used for compassionate treatment of relapses. In 
Chagas disease, the dose used in adults is 8–10 mg/kg 
per day for 30–120 days. Toxic eﬀ   ects are mainly 
neurological (headache, sleep dysfunction, agitation, 
confusion) and gastrointestinal (anorexia, nausea/
vomiting, dyspepsia) disorders,
18 some of which are 
dependent on the duration of drug intake.
14,16
Combination treatments of these drugs with lower 
doses of each component might reduce overall toxicity 
while maintaining good eﬃ   cacy. They might also prevent 
or delay the emergence of drug-resistant organisms and 
allow for simpler administration regimens. We ﬁ  rst 
assessed three-drug combinations in a trial started in 
Uganda in 2001, which was terminated early because of 
excess toxicity in both melarsoprol-containing groups. By 
contrast, the nifurtimox-eﬂ  ornithine combination seemed 
safer and eﬃ   cacious.
19 A second study that assessed 
nifurtimox-eﬂ  ornithine in 31 Ugandan patients showed 
similar results.
20 On the basis of these encouraging 
ﬁ  ndings, a third study was started in 2003 in the Republic 
of the Congo, to assess a nifurtimox-eﬂ  ornithine 
combination treatment (NECT) with the same doses but a 
simpler administration schedule. The new regimen was 
compared with standard eﬂ   ornithine treatment in a 
randomised, open-label, non-inferiority clinical study 
design.
21 This study was extended to three new sites in the 
Democratic Republic of the Congo (DR Congo) from 
2005, becoming the multicentre trial reported here, which 
includes recruited patients from the four sites.
The objectives of this study were to assess the eﬃ   cacy 
and safety of NECT for the treatment of second-stage 
T b gambiense HAT. The study was designed to assess the 
non-inferiority (eﬃ     cacy) of NECT against eﬂ  ornithine 
monotherapy, the best treatment available.
Methods
Participants
This open-label, randomised, phase III, non-inferiority 
trial took place in four HAT treatment centres: Nkayi, 
(Republic of the Congo), Isangi, Dipumba, and Katanda 
(DR Congo). To allow comparison of our results with 
those of others, the methodology was aligned with recent 
clinical trials on second-stage trypanosomiasis
13,19,22,23 and 
complied with Good Clinical Practice (GCP) guidelines.
Participants were identiﬁ  ed by routine diagnosis of 
HAT or during active screening campaigns. Patients 
aged 15 years or older with second-stage T b gambiense 
infection with trypanosomes detected in blood, lymph 
node ﬂ  uid, or cerebrospinal ﬂ  uid (CSF), and more than 
20 leucocytes per μL in CSF were eligible for enrolment. 
Exclusion criteria included pregnancy, history of previous 
second-stage HAT treatment, severe comorbidities with 
poor chance of survival, haemoglobin concentration less 
than 50 g/L, and inability to complete 18 months of 
follow-up.
131 completed follow-up
129 cured at 18 months
2 relapsed
9 partial follow-up
3 died of HAT-unrelated causes
2 moved away
4 refused further assessment
2 no follow-up
1 died of HAT-unrelated cause before any 
   eﬃcacy assessment
1 refused all follow-up
131 completed follow-up
123 cured at 18 months
8 relapsed
8 partial follow-up
2 died of HAT-unrelated causes
2 moved away
4 refused further assessment
1 no follow-up
1 died of HAT-unrelated cause before any 
   eﬃcacy assessment
143 included in ITT population
141 included in mITT population 
(excluding those with no follow-up)
132 included in PP population (including 
only those with complete follow-up 
and a study endpoint)
143 included in ITT population*
142 included in mITT population 
(excluding those with no follow-up)
133 included in PP population (including 
only those with complete follow-up and 
a study endpoint)†
140 followed up 142 followed up
144 assigned to eﬂornithine 143 assigned to NECT
287 randomised
1534 patients screened
1247 ineligible
586 stage 1 disease
319 relapsing after treatment
102 age <15 years
  84 low CSF leucocyte count
156 other reasons
1 absconded on day 1
3 died
1 died
Figure 1: Trial proﬁ  le
NECT=nifurtimox-eﬂ  ornithine combination treatment. HAT=human African trypanosomiasis. ITT=intention-to-
treat. mITT=modiﬁ  ed intention-to-treat. PP=per-protocol. *All randomised patients, apart from one who 
absconded on day 1. †One patient was excluded from the PP population because of a major protocol deviation.Articles
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Four ethics committees approved the study protocol: 
Médecins Sans Frontières International Ethical Review 
Board (Geneva, Switzerland); Comité Consultatif de 
Protection des Personnes dans la Recherche Biomédicale 
(CCPPRB; Saint-Germain-en-Laye, France); WHO 
Research Ethics Committee (Geneva, Switzerland); and 
Comité d’Ethique du Ministère de la Santé (DR Congo). 
All participants gave signed or ﬁ  ngerprinted informed 
consent. An independent data safety and monitoring 
board reviewed the study regularly.
Randomisation and masking
Patients were randomised to intervention and control 
groups in a 1:1 ratio without any stratiﬁ  cation.  The 
randomisation list (in blocks of ten) was electronically 
generated at Epicentre headquarters (Paris, France) and 
concealed from the ﬁ   eld teams that enrolled and 
allocated treatments. Participants were enrolled in the 
same order in which they were diagnosed. Sealed and 
numbered opaque envelopes contained the treatment 
allocation and were opened in strict numeric sequence. 
Masking was not feasible because the method of drug 
administration diﬀ  ered between the two groups.
Procedures
Drug regimens were based on the existing evidence 
including early data from the precursor studies.
19,20 
Participants in the intervention group were given 
intravenous eﬂ  ornithine (400 mg/kg per day, every 12 h) 
for 7 days, with oral nifurtimox (15 mg/kg per day, every 
8 h) for 10 days (NECT). The active comparator was 
intravenous eﬂ  ornithine (400 mg/kg per day, every 6 h), 
given for 14 days. Eﬂ  ornithine was diluted in 250 mL of 
normal saline and infused over 2 h. Nifurtimox intake 
was directly observed, and re-administered if vomiting 
occurred within 30 min. Speciﬁ   c rules dealt with 
treatment interruptions in each group. Depending on 
the length of the interruption and the time it occurred 
during the treatment course, interruptions considered 
likely to aﬀ  ect eﬃ   cacy were compensated with additional 
doses of eﬂ  ornithine.
Patients with malaria received artemether-lume  fan-
trine for 3 days, with the study treatment starting at 
least 1·5 days after this treatment. Drugs for other 
concomitant disorders were postponed until the end of 
hospital admission, unless immediate treatment was 
warranted. Patients received a food ration of 2100 kcal 
per day. 
All patients were medically assessed daily, and remained 
in hospital for 7 days after the end of treatment, or longer 
if needed. A lumbar puncture was done 1 day after the 
last study dose, to examine CSF for trypanosomes and to 
obtain a leucocyte count. Follow-up laboratory 
examinations were done at 6, 12, and 18 months, and 
included testing for trypanosomes in the blood (capillary 
tube centrifugation and quantitative buﬀ  y  coat
24 
techniques), CSF, and lymph node ﬂ   uid, and CSF 
leucocyte count. Trypanosome observation and CSF 
leucocyte counts were conﬁ  rmed  through  two 
independent readings by diﬀ  erent laboratory technicians 
and the mean values were recorded. Discrepancies were 
resolved by a third reading taken by a senior technician.
Paticipants were followed up for 18 months, as 
recommended by a consensus of HAT experts
25 on the 
basis of data suggesting that 70–90% of relapses occur 
Eﬂ  ornithine NECT
N n (%) or mean (SD)* N n (%) or mean (SD)*
Demographic characteristics
Men 143 89 (62%) 143 84 (59%)
Age (years) 143 34·6 (13·5) 142 32·8 (12·5)
Weight (kg) 143 53·9 (8·7) 143 53·0 (8·3)
Height (cm) 143 165·8 (9·1) 143 165·8 (7·9)
Body-mass index <18·5 kg/m² 143 47 (33%) 143 54 (38%)
Parasitological ﬁ  ndings
Detected by active screening 143 51 (36%) 143 59 (41%)
Presence of trypanosomes 
in lymph nodes 143 88 (62%) 143 88 (62%)
in blood 143 74 (52%) 143 67 (47%)
in CSF 142 105 (74%) 143 103 (72%)
Leucocyte count in CSF
6–20 cells per μL 143 2 (1%) 143 2 (1%)
21–99 cells per μL 143 26 (18%) 143 34 (24%)
 ≥100 cells per μL 143 115 (80%) 143 107 (75%)
Clinical characteristics
Haemoglobin (g/L) 143 118 (18·6) 143 119 (19·2)
Malaria co-infection 142 29 (20%) 143 22 (15%)
Lymphadenopathy 143 88 (62%) 143 88 (62%)
Hepatomegaly 143 6 (4%) 143 9 (6%)
Splenomegaly 143 29 (20%) 142 21 (15%)
Coma score† <15 142 6 (4%) 142 13 (9%)
Karnofsky index‡ (median [mean, (SD)]) 143 80 (77·1 [12·8]) 143 80 (75·3 [15·7])
Fever§ 143 29 (20%) 143 22 (15%)
Headache 142 119 (84%) 143 115 (80%)
Pruritus 142 102 (72%) 142 104 (73%)
Amenorrhoea¶ 40 19 (48%) 48 23 (48%)
Impotence 86 42 (49%) 81 46 (57%)
Unusual behaviour 140 66 (47%) 141 56 (40%)
Anorexia 142 42 (30%) 142 53 (37%)
Seizures 142 16 (11%) 143 10 (7%)
Tremors 141 51 (36%) 143 51 (36%)
Diurnal somnolence 143 109 (76%) 142 96 (68%)
Nocturnal insomnia 142 65 (46%) 142 59 (42%)
Speech disorder 143 24 (17%) 142 29 (20%)
Neurological signs 143 49 (34%) 141 52 (37%)
Duration of symptoms (months) 142 8·5 (9·2) 142 8·6 (9·4)
NECT=nifurtimox-eﬂ  ornithine combination treatment. CSF=cerebrospinal ﬂ  uid. *Unless otherwise indicated. 
†Coma score uses the Glasgow Coma Score: sum of points obtained in each of three criteria (best motor response, 
best verbal response, eye opening). 3–8 being severe impairment; 9–12 moderate impairment; 13–14 mild 
impairment; and 15 normal. ‡The Karnofsky index runs from 100 to 0, where 100 is normal health and 0 is death. 
§Fever deﬁ  ned as axillary temperature 37·5°C or more. ¶Amenorrhoea assessed in women aged 51 years or younger.
Table 1: Baseline characteristics of trial participants, by treatment groupArticles
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within this period, and therefore considered suﬃ   cient 
for comparative eﬃ     cacy evaluations in randomised 
trials. A relapse was diagnosed if trypanosomes were 
seen in any body ﬂ   uid or if CSF leucocyte count 
increased twice consecutively by 20 cells per μL or more. 
Patients with a single increase were re-examined 
1 month later. At 18 months, a relapse was deﬁ  ned as 
leucocyte count more than 20 cells per μL, irrespective 
of previous counts. No distinction was made between 
relapse and re-infection because of technological 
limitations. Within the epidemiological context of the 
four sites, the probability of re-infection was judged to 
be low.
Safety was assessed by use of the National Cancer 
Institute Common Toxicity Criteria,
26 which grades 
adverse events by intensity from 1 to 4 (mild, moderate, 
severe, or very severe), drug–event relation (unrelated, 
unlikely, possible, probable, or deﬁ  nite), and outcome 
(recovery, still present, sequelae, or death). Blood samples 
taken before, immediately after, and 7 days after treatment 
were examined for haemoglobin concentration, leucocyte 
count, and concentrations of creatinine, alanine 
aminotransferase, and total bilirubin.
The primary outcome was cure, deﬁ  ned as absence of 
trypanosomes in body ﬂ  uids and a CSF leucocyte count 
20 cells per μL or less at 18 months. Endpoints regarded 
as therapeutic failure were death in temporal relation to 
treatment (within 30 days of treatment start), relapse of 
HAT or death compatible with HAT during follow-up, 
and complete loss to follow-up. Deaths without a clearly 
established alternative cause were regarded as HAT-
related. Patients missing the 18-month laboratory 
examination were deemed probably cured if they were 
seen by the investigators after 18 months and were found 
in good physical and mental health, or if their last 
laboratory examination showed a favourable evolution 
(this includes patients who died later of causes unrelated 
to HAT). Favourable evolution was deﬁ  ned as a decrease 
of CSF leucocyte count or an increase of less than 
20 leucocytes per μL. Safety outcomes were clinical and 
laboratory adverse events temporally associated with the 
treatment, in particular the major adverse events: severe 
(grade 3) and very severe (grade 4).
Statistical analysis
The non-inferiority margin for the diﬀ  erence in cure 
rates between groups was deﬁ   ned as 10% by the 
scientiﬁ  c committee, considering the high eﬃ   cacy of 
the comparator and the crucial need of therapeutic 
alternatives. The control treatment (eﬂ  ornithine 
monotherapy) has never been tested against placebo. At 
the time of the protocol development, available data 
showed eﬀ  ectiveness estimations with eﬂ  ornithine in a 
Favours NECT
Diﬀerence (90% CI)
ITT
mITT
PP
–15 –10 –5 0 5 10 15
Favours eﬂornithine
Figure 2: Overall cure rates (non-inferiority analysis) by analysis population
NECT=nifurtimox-eﬂ  ornithine combination treatment. ITT=intention-to-treat. 
mITT=modiﬁ  ed intention-to-treat. PP=per-protocol. Diﬀ  erence (Δ) of cure rates 
between the standard eﬂ  ornithine regimen and NECT (eﬂ  ornithine–NECT), and 
90% CIs around Δ. The dotted lines indicates the non-inferiority margin (zone of 
non-inferiority lies to the left of Δ=10%, and the zone of superiority lies to the 
left of Δ=0%).
Eﬂ  ornithine NECT Diﬀ  erence 
Δ (%)
One-sided 
95% CI*
p value
n/N % 95% CI n/N % 95% CI
Primary analysis
Cure rate
ITT population 131/143 91·6% ·· 138/143 96·5% ·· –4·9% –0·3 <0·0001†
mITT population 131/142 92·3% ·· 138/141 97·9% ·· –5·6% –1·4 <0·0001†
PP population 122/133 91·7% ·· 129/132 97·7% ·· –6·0% –1·5 <0·0001†
Secondary analysis (ITT population)
Probability of event-free survival‡ ·· 84·8% 70·1–92·7 ·· 94·3% 78·3–98·6 ·· ·· 0·0497§
Relapse at 12 months 5/140 3·6% 1·2–8·1 0/142 0·0% 0·0–2·6¶ ·· ·· 0·029
Relapse at 18 months 8/140 5·7% 2·5–10·9 2/142 1·4% 0·0–5·0 ·· ·· 0·029
Parasitologically conﬁ  rmed relapse 5/140 3·6% 1·2–8·1 0/142 0·0% 0·0–2·6¶ ·· ·· 0·029
Fatality (within 30 days) 3/143 2·1% 0·4–6·0 1/143 0·7% 0·0–3·8 ·· ·· 0·622
NECT=nifurtimox-eﬂ  ornithine combination treatment. ITT=intention-to-treat (all randomised patients, apart from one who absconded on day 1). mITT=modiﬁ  ed 
intention-to-treat (including patients with partial or complete follow-up but excluding those with no follow-up). PP=per-protocol (including only patients with complete 
follow-up and a study endpoint). *According to the Blackwelder method:
27 upper limit of a two-sided 90% CI around the diﬀ  erence (Δ) of cure rates. †p values testing the 
10% non-inferiority margin. ‡Events included relapse of human African trypanosomiasis (HAT) and death related to HAT or to treatment. §Log-rank test. ¶One-sided, 
97·5% CI. 
Table 2: Eﬃ   cacy outcome by treatment group (primary and secondary analyses)Articles
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range of 89% to 97%. Assuming a 93% cure rate with 
the control regimen, a maximum diﬀ  erence in cure 
rates between the groups of 10%, and a similar dropout 
rate in the two groups, we calculated that a sample size 
of 280 patients (140 per group) was needed to determine 
non-inferiority with a power of 90% at an alpha error of 
5% (one-sided test).
Data were recorded on speciﬁ   cally designed patient 
charts, and relevant trial data were extracted in case 
report forms. These data were double-entered 
electronically with EpiData version 3.0 and analysed with 
Stata version 9.2. The eﬃ   cacy analyses were done on 
three populations: intention-to-treat (ITT), modiﬁ  ed ITT, 
which included patients with partial or complete follow-
up but excluded those with no follow-up, and per-protocol 
(PP), which included only those with complete follow-up 
and a study endpoint. Non-inferiority of NECT was tested 
by use of the Blackwelder
27 method by calculating the 
diﬀ  erence of overall cure rates and comparing its one-
sided 95% CI (or upper limit of the 90% CI) to the non-
inferiority margin. Overall cure included cure and 
probable cure. Secondary eﬃ   cacy  analyses  included 
comparison of proportions and survival analysis (Kaplan-
Meier method, comparison of distributions by log-rank 
test). Proportions (eﬃ   cacy and safety) were compared 
with χ² or Fisher’s exact test and two-sided p values. This 
study is registered with ClinicalTrials.gov, number 
NCT00146627.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ  nal 
responsibility for the decision to submit for publication.
Results
Enrolment at the ﬁ  rst site started in August, 2003, and at 
the following three sites in 2005, and 2006, concluding in 
November, 2006. Follow-up was completed in June, 2008. 
Figure 1 shows the trial proﬁ  le. One patient assigned to 
eﬂ  ornithine monotherapy absconded after receiving the 
ﬁ  rst dose, without any type of assessment done, and was 
excluded from all analyses.
Table 1 shows the baseline characteristics of trial 
participants. All patients received complete treatment. 
Protocol deviations were rare: four patients (two per group) 
were enrolled with CSF leucocyte count 5–20 cells per μL, 
but trypanosomes were present in the CSF. One patient 
(NECT group) received eﬂ  ornithine for 10 days instead of 
7 days. There was an error in the eﬃ   cacy  assessment 
(diagnosis of relapse) of one patient in the eﬂ  ornithine 
group that was regarded as a major protocol violation. This 
patient was excluded from the PP population. 
283 (99%) of 286 participants had at least one follow-up 
assessment or reached a study endpoint earlier, 266 (93%) 
completed 18 months follow-up or reached a study 
endpoint earlier, 17 (6%) had a partial follow-up, and three 
(1%) had no follow-up. All 17 patients with partial follow-
up showed a favourable evolution in CSF leucocyte count 
at their last assessment and were deemed probably cured 
(eﬂ  ornithine, n=8 NECT, n=9). 13 patients seen by the 
investigators at 18 months were in good physical and 
mental health but refused laboratory assessments (also 
regarded as probably cured; eﬂ  ornithine, n=7 NECT, n=6). 
Thus, 15 patients in each group were judged to be probably 
cured. Of the three patients without follow-up, two died 
of unrelated causes and one refused all assessments. 
These patients were deemed treatment failures.
Eﬂ  ornithine (N=143) NECT (N=143) p value
n (%)* Number of 
major 
events†
n (%)* Number of 
major 
events†
Neurological 60 (42·0%) 9 60 (42·0%) 9 1·000
Seizures 13 (9·1%) 6 18 (12·6%) 6 0·342
Confusion 2 (1·4%) 1 6 (4·2%) 2 0·282
Anxiety/agitation 11 (7·7%) 1 4 (2·8%) 0 0·109
Dizziness 24 (16·8%) 0 26 (18·2%) 0 0·756
Ataxia 2 (1·4%) 0 5 (3·5%) 1 0·447
Inner ear disturbance 7 (4·9%) 0 10 (7·0%) 1 0·365
Tremors 1 (0·7%) 0 9 (6·3%) 0 0·019
Coma 3 (2·1%) 3 1 (0·7%) 1 0·622
Amnesia 1 (0·7%) 0 1 (0·7%) 0 1·000
Insomnia 14 (9·8%) 0 14 (9·8%) 0 1·000
Hallucinations 1 (0·7%) 1 2 (1·4%) 1 1·000
Lethargy 2 (1·4%) 0 0 (0·0%) 0 0·498
Mood alteration (depression) 1 (0·7%) 0 2 (1·4%) 0 1·000
Peripheral neuropathy (motor) 2 (1·4%) 1 4 (2·8%) 1 0·684
Peripheral neuropathy (sensory) 5 (3·5%) 0 5 (3·5%) 0 1·000
Gastrointestinal 78 (54·5%) 2 106 (74·1%) 2 0·001
Anorexia 20 (14·0%) 0 36 (25·2%) 1 0·017
Dysphagia 12 (8·4%) 0 3 (2·1%) 0 0·031
Hiccups 3 (2·1%) 0 6 (4·2%) 0 0·501
Taste disturbance 2 (1·4%) 0 1 (0·7%) 0 1·000
Mouth dryness 7 (4·9%) 0 1 (0·7%) 0 0·066
Regurgitation 0 (0·0%) 0 2 (1·4%) 0 0·498
Abdominal pain 42 (29·4%) 0 35 (24·5%) 0 0·351
Diarrhoea 41 (28·7%) 2 9 (6·3%) 0 <0·0001
Constipation 6 (4·2%) 0 4 (2·8%) 0 0·749
Nausea and/or vomiting 29 (20·3%) 0 69 (48·3%) 1 0·000
Cardiovascular 49 (34·3%) 3 29 (20·3%) 0 0·008
Arrythmia 31 (21·7%) 0 27 (18·9%) 0 0·556
Hypertension 19 (13·3%) 3 6 (4·2%) 0 0·006
Oedema 6 (4·2%) 0 1 (0·7%) 0 0·120
Hypotension/shock 4 (2·8%) 0 5 (3·5%) 0 1·000
Infection 25 (17·5%) 5 14 (9·8%) 1 0·058
Tissue infection 2 (1·4%) 0 6 (4·2%) 0 0·282
Injection site infection 5 (3·5%) 0 4 (2·8%) 0 1·000
Pneumonia 2 (1·4%) 2 0 (0·0%) 0 0·498
Other infections 23 (16·1%) 5 8 (5·6%) 1 0·004
(Continues on next page)Articles
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Four deaths temporally related to the treatment were 
judged treatment failures (eﬂ  ornithine, n=3; NECT, n=1). 
There were ten relapses (eﬂ  ornithine, n=8; NECT, n=2), 
ﬁ  ve of which were detected before 18 months (range 
6·1–14·5 months) and the rest at 18 months or later 
(18·3–20·9 months; table 2). Five relapses were diagnosed 
by presence of trypanosomes in CSF (all in the 
eﬂ  ornithine group), the other ﬁ  ve relapses were diagnosed 
on the basis of increases in CSF leucocyte count. Patients 
with relapse were treated according to national protocols 
and clinicians’ judgment.
Table 2 shows the cure rates by treatment group and 
analysis population (ITT, modiﬁ  ed ITT, and PP). In the 
ITT population, 131 (91·6%) of 143 patients assigned to 
eﬂ  ornithine and 138 (96·5%) of 143 patients assigned to 
NECT were cured or probably cured at 18 months 
(diﬀ  erence –4·9%, one-sided 95% CI –0·3; p<0·0001). In 
the PP population, 122 (91·7%) of 133 patients in the 
eﬂ  ornithine group and 129 (97·7%) of 132 in the NECT 
group were cured at 18 months (diﬀ  erence –6·0%, one-
sided 95% CI –1·5; p<0·0001). Results were similar in 
the three analysis populations (ﬁ  gure 2).
Although not originally planned, we also undertook a 
sensitivity analysis (worst-case scenario), which included 
all patients (apart from the one who absconded) and 
judged as cured only those patients with laboratory-
conﬁ  rmed cure at 18 months. All other patients (relapses, 
all-cause deaths, lost to follow-up, probable cures) were 
analysed as failures. In this analysis, 116 (81·1%) of 
143 controls and 123 (86·0%) of 143 patients in the NECT 
group were cured (diﬀ  erence –4·9%, one-sided 95% CI 
0·02; p=0·0003). Secondary eﬃ   cacy analyses (table 2) 
showed that relapse rates (at 12 months and 18 months) 
and parasitologically conﬁ  rmed relapse rates were lower, 
and the probability of event-free survival was higher in 
the NECT group than in the eﬂ  ornithine group.
The three deaths in the eﬂ   ornithine group were 
attributed to septic shock (following severe neutropenia), 
pneumonia, and urinary infection with coma. The death 
in the NECT group was attributed to respiratory distress 
syndrome. All four deaths were judged related to study 
drugs. Of 1363 clinical adverse events recorded, 101 were 
judged by the clinicians as not related to treatment, and 
1262 events were judged as drug related (table 3). There 
were 132 laboratory-detected adverse events (table 4). The 
total number of drug-related events was therefore 1394, 
and the number of reactions per patient was 5·3 
(eﬂ  ornithine) and 4·5 (NECT). 
The proportion of patients who had major (grade 3–4) 
drug-related adverse events (table 5) was lower in the 
NECT group than in the eﬂ  ornithine group (20/143 [14·0%] 
vs 41/143 [28·7%]; p=0·002), mainly because of a lower 
frequency of severe fever, infections, neutropenia, 
hypertension, and diarrhoea. Temporary treatment 
interruptions were necessary in nine (6·3%) of 
143 patients assigned to eﬂ  ornithine (duration ranging 
from 6 h to 6 days) and one (0·7%) of 143 patients 
assigned to NECT (duration 1 day; p=0·019) All treatment 
schedules were adapted (or not) according to the 
protocol.
In terms of speciﬁ  c types of reactions, patients in the 
NECT group had a lower frequency of diarrhoea, 
hypertension, infections, dysphagia, pruritus, skin rash, 
fever, and neutropenia than did controls. However, 
nausea and vomiting, anorexia, and tremors were more 
frequent in patients assigned to NECT. The clinicians 
noted that nausea and vomiting tended to appear at least 
1 h after nifurtimox intake and more frequently after the 
simultaneous administration of both drugs (ﬁ  rst daily 
dose) than when nifurtimox and eﬂ  ornithine were given 
at diﬀ  erent times. Nausea did not impede the intake 
(supervised) of nifurtimox tablets.
Neutropenia and anaemia were the most prominent 
haematological reactions (table 4). The frequency of 
neutropenia was signiﬁ  cantly lower in patients assigned to 
NECT than in controls (p=0·001). Grade 3 neutropenia 
(less than 1000 neutrophils per μL) developed in 12 patients 
(eﬂ   ornithine, n=10, NECT, n=2; p=0·019). Abnormal 
biochemical values were rare and mild in both groups.
Of all laboratory abnormalities that developed during 
treatment, 70 (53%) of 132 were re-examined 7 days later. 
Laboratory markers returned to normal levels or improved 
Eﬂ  ornithine (N=143) NECT (N=143) p value‡
n (%)* Number of 
major 
events†
n (%)* Number of 
major 
events†
(Continued from previous page) 
Other clinical events 122 (85·3%) 20 101 (70·6%) 10 0·003
Fever§ 61 (42·7%) 18 37 (25·9%) 7 0·003
Headache 66 (46·2%) 2 55 (38·5%) 1 0·188
Asthenia 28 (19·6%) 1 34 (23·8%) 0 0·389
Cough 14 (9·8%) 0 10 (7·0%) 0 0·394
Pruritus 27 (18·9%) 0 13 (9·1%) 0 0·017
Skin rash 20 (14·0%) 0 4 (2·8%) 1 0·001
Injection site reaction 16 (11·2%) 0 14 (9·8%) 0 0·700
Extravasation 11 (7·7%) 0 6 (4·2%) 0 0·211
Chest pain 15 (10·5%) 1 10 (7·0%) 0 0·295
Dehydration 3 (2·1%) 0 3 (2·1%) 1 1·000
Urinary incontinence 4 (2·8%) 0 4 (2·8%) 0 1·000
Urinary frequency/urgency 6 (4·2%) 0 2 (1·4%) 0 0·282
Myalgia/arthralgia 43 (30·1%) 0 43 (30·1%) 0 1·000
Dyspnoea 1 (0·7%) 0 2 (1·4%) 0 1·000
Respiratory distress 1 (0·7%) 1 1 (0·7%) 1 1·000
Epistaxis 2 (1·4%) 0 0 (0·0%) 0 0·498
Other 16 (11·2%) 0 17 (11·9%) 0 0·853
NECT=nifurtimox-eﬂ  ornithine combination treatment. The total number of clinical events was 677 (48 major) in the 
eﬂ  ornithine group and 585 (27 major) in the NECT group. *All ﬁ  gures indicate the number of patients with a given 
type of adverse event (please note, one patient might have had more than one type of event from each category 
[eg, neurological]). †An event was deﬁ  ned as major if it was classed as grade 3 (severe) or grade 4 (very severe) 
according to the National Cancer Institute Common Toxicity Criteria.
26 ‡Comparison for number of patients with a 
given event. §Fever deﬁ  ned as axillary temperature 37·5°C or more.
Table 3: Number of patients with drug-related adverse events, by treatment groupArticles
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in most patients (53 [76%]), but remained unchanged in 
14 (20%) patients. Reactions had worsened only in the 
eﬂ  ornithine group (three of 39 [8%]: one case of neutropenia 
and two cases of thrombopenia).
Discussion
This multicentre study was done in four rural HAT-
endemic areas that were thousands of kilometres apart. 
These regions are characterised by political instability, 
poor infrastructure, inadequate research capacity, and 
geographic dispersion of patients. Despite these 
challenges, the methods used in this trial complied with 
international GCP guidelines. The results show that the 
eﬃ   cacy of NECT is non-inferior to standard eﬂ  ornithine 
monotherapy (10% non-inferiority margin). High cure 
rates of 96·5% to 97·9% (depending on the analysis 
population) were seen in patients assigned to NECT, 
compared with rates of 91·6% to 92·3% in patients 
assigned to eﬂ   ornithine. The results of the post-hoc 
worst-case scenario analysis were similar to the results of 
the primary analysis, and provided evidence that there 
was no potential bias related to the patients with 
incomplete follow-up.
Theoretically, because of the short half-life of 
eﬂ   ornithine, 6-h infusions are needed to obtain a 
constant trypanostatic eﬀ  ect. Our data show that 12-h 
eﬂ   ornithine infusions are highly eﬀ  ective  when 
combined with oral nifurtimox. A possible explanation 
is that the irreversible ornithine decarboxylase inhibition 
caused by eﬂ  ornithine arrests the parasite’s defences for 
about 18–19 h, the time needed to replenish enzyme 
concentrations,
28 facilitating the trypanocidal action of 
nifurtimox by oxidative stress.
A common limitation of previous eﬃ   cacy studies of 
HAT treatment has been poor follow-up, owing to 
contextual and behavioural factors. Follow-up compliance 
in this study was high, thus enhancing the robustness of 
the eﬃ     cacy evaluation. Half of the relapses became 
detectable at 18 months or later, despite all patients 
having had interim assessments. In accordance with 
former studies,
29 these data suggest that follow-up in 
clinical studies that include these drugs should be no 
shorter than 18 months.
The results of this study show that this drug 
combination is fairly well tolerated. Notably, low fatality 
rates (0·7%) were associated with NECT, by contrast with 
the 5–6% reported fatality after treatment with 
melarsoprol,
2,30 the most widely used drug for treatment 
of HAT. Drug-related adverse events were frequent in 
both trial groups. However, it must be appreciated that it 
is diﬃ   cult to discern the causality between the disease 
itself, comorbidities, concomitant treatments, and the 
study treatment. Our description is conservative: events 
are deemed treatment-related unless the investigators 
were certain to the contrary.
Because HAT is a fatal condition, and adverse events 
are very common during treatment, we focused the 
assessment on major (severe and very severe) drug-
related adverse events. Half as many major adverse 
events were reported in the NECT group than in the 
eﬂ  ornithine group (p=0·002). Additionally, NECT was 
associated with a lower frequency of infections, diarrhoea, 
fever, dysphagia, hypertension, pruritus, skin rash, and 
neutropenia than was eﬂ  ornithine monotherapy, whereas 
nausea and vomiting, anorexia, and tremors were more 
frequent. Although 48% of patients assigned to NECT 
had nausea or vomiting, or both, which could potentially 
aﬀ  ect nifurtimox absorption, the eﬃ   cacy of treatment 
Eﬂ  ornithine NECT p value†
n/N (%) Number 
of major 
events*
n/N (%) Number 
of major 
events*
Patients with haematological 
reactions
58/143 (40·6%) 11 30/143 (21·0%) 4 0·0003
Anaemia‡ 12/141 (8·5%) 1 10/142 (7·0%) 2 0·645
Leucopenia§ 6/139 (4·3%) 0 8/142 (5·6%) 0 0·612
Neutropenia¶ 46/139 (33·1%) 10 22/142 (15·5%) 2 0·001
Thrombopenia 4/93 (4·3%) 0 1/87 (1·1%) 0 0·369
Patients with biochemical reactions 9/143 (6·3%) 0 11/143 (7·7%) 0 0·643
Abnormal creatinine|| 1/129 (0·8%) 0 1/128 (0·8%) 0 1·000
Abnormal bilirubin** 6/131 (4·6%) 0 9/128 (7·0%) 0 0·398
Abnormal alanine 
aminotransferase††
4/131 (3·1%) 0 2/127 (1·6%) 0 0·684
Patients with any laboratory reaction 66/143 (46·2%) 11 38/143 (26·6%) 4 0·001
NECT=nifurtimox-eﬂ  ornithine combination treatment. The total number of laboratory reactions was 79 (11 major) in 
the eﬂ  ornithine group and 53 (four major) in the NECT group *An event was deﬁ  ned as major if it was classed as grade 3 
(severe) or grade 4 (very severe) according to the National Cancer Institute Common Toxicity Criteria.
26 †Comparison for 
number of patients with a given event. ‡Anaemia deﬁ  ned as haemoglobin less than 130 g/L (men) and less than 110 g/L 
(women), having decreased by more than 20%. §Leucopenia deﬁ  ned as less than 4000 leucocytes per μL, having 
decreased by more than 30%. ¶Neutropenia deﬁ  ned as less than 2000 neutrophils per μL, having decreased by more 
than 30%. ||Abnormal creatinine deﬁ  ned as more than 80 μmol/L (women) and 97 μmol/L (men), having increased by 
more than 1·5 times. **Abnormal bilirubin deﬁ  ned as more than 17 μmol/L, having increased by more than 1·5 times. 
††Abnormal alanine aminotransferase deﬁ  ned as more than 12 IU/L (reagents from Randox, UK, and Roche, 
Switzerland) and more than 32 IU/L (women) and more than 42 UI/L (men; subgroup measured with reagents from 
Human, Germany), having increased by more than 2·5 times.
Table 4: Number of patients with laboratory drug-related adverse events, by treatment group
Eﬂ  ornithine (N=143) NECT (N=143) p value
Patients with major drug-related adverse events 41 (28·7%) 20 (14·0%) 0·002
Clinical 33 (23·1%) 18 (12·6%) 0·020
Laboratory 11 (7·7%) 4 (2·8%) 0·109
Patients with any drug-related adverse events 138 (96·5%) 136 (95·1%) 0·555
Clinical 134 (93·7%) 134 (93·7%) 1·000
Weight loss ≥5% 5 (3·5%) 6 (4·2%) 0·758
Laboratory 66 (46·2%) 38 (26·6%) 0·001
Patients with serious adverse events 6 (4·2%) 1 (0·7%) 0·120
Patients with temporary treatment interruptions 9 (6·3%) 1 (0·7%) 0·019
Deaths related to treatment 3 (2·1%) 1 (0·7%) 0·622
NECT=nifurtimox-eﬂ  ornithine combination treatment. Data are n (%). An event was deﬁ  ned as major if it was classed 
as grade 3 (severe) or grade 4 (very severe) according to the National Cancer Institute Common Toxicity Criteria.
26 An 
event was deﬁ  ned as serious if it was fatal, life-threatening, or resulted in long hospital stay, substantial disability, or 
congenital anomaly.
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was remarkably good. This fact, in addition to the bedside 
observations on the timing of vomiting (at least 1 h after 
nifurtimox intake, more frequently after the concomitant 
administration of both drugs), suggest that vomiting was 
provoked at cerebral level by simultaneous peak 
concentrations of both drugs. On the basis of these 
ﬁ  ndings, we suggest that adjustments in the timing of 
drug intake might alleviate nausea and vomiting. Future 
studies should include collection of prospective data on 
the timing of vomiting.
The reduced bone marrow toxicity, reﬂ   ected by the 
lower frequency of neutropenia and anaemia in the 
NECT group than in the eﬂ  ornithine group, is consistent 
with the halved eﬂ  ornithine exposure (control 14 days vs 
NECT 7 days). This reduced exposure might explain the 
lower overall frequency of infections, an eﬀ  ect reinforced 
by a reduction in catheter-related infections expected 
with the substantial reduction (56 vs 14) in the number of 
infusions. In standard practice, patients return home 
immediately after treatment, and neutropenic cases 
remain vulnerable to bacterial infections for 1–2 weeks. A 
reduced risk of infections can be expected with the use of 
NECT.
Our study has potential limitations. We had to use an 
open-label design, which was unavoidable because of the 
diﬀ  erent methods of drug administration in the treatment 
groups. However, eﬃ     cacy outcomes were mainly 
established by laboratory results, which were always 
conﬁ  rmed by two independent readings. A limitation in 
the safety analysis is that the hospital admission time 
diﬀ  ered per group, because of the diﬀ  erent treatment 
schedules. (The longer a patient stays in hospital under 
observation, the more adverse events are likely to occur 
and be recorded.)
The overwhelming consensus among experts working 
on HAT and aﬀ  ected populations stresses the urgent 
need to identify feasible, safe, and eﬀ  ective therapies for 
second-stage disease.
2 This study suggests that NECT is 
safe and eﬀ  ective for the treatment of T b gambiense 
infection. The results are consistent with our two previous 
studies investigating this drug combination.
19,20 However, 
the results are not applicable to patients infected with 
T b rhodesiense; this infection would require its own 
speciﬁ  c studies.
NECT is easier to administer and less demanding on 
human and material resources than eﬂ  ornithine 
monotherapy because it has a simpler administration 
schedule and requires shorter hospital stay. These 
characteristics are important because most treatment 
centres are in remote locations, with logistical and 
staﬃ   ng limitations. NECT is also more aﬀ  ordable, mainly 
because the four-fold reduction of intravenous infusions 
implies savings in the purchase, transportation, and 
stocking of intravenous ﬂ  uids and injection materials, in 
hospital staﬀ   (overall patient management but especially 
night duties), and in management of catheter-related 
infections and other adverse events. Additionally, NECT 
uses half the amount of expensive eﬂ  ornithine  while 
adding a small amount of inexpensive nifurtimox. The 
lower cost and simpler  logistics of NECT could alleviate 
the burden on HAT control programmes.
This combination of drugs with diﬀ  erent mechanisms 
of action might be protected against the development of 
drug resistance, as is the case for drug combinations 
used in other infectious diseases. There is already an 
established and growing parasite resistance to 
melarsoprol, and the increasing large-scale use of 
eﬂ  ornithine monotherapy could see this drug exposed to 
the same threat. To avert the development of eﬂ  ornithine 
resistance, full-scale implementation of the NECT 
regimen should be a priority for HAT control 
programmes.
Contributors
The authors accept full responsibility for the overall content of this 
report. GPr designed and coordinated the study, contributed to data 
analysis, and wrote the manuscript. SK set up the study in the ﬁ  eld, 
undertook training, monitoring, and supervision, enrolled and 
managed patients, collected clinical data, and participated in writing 
the report. WMuto, DN, SGho, UA, VB, SK-K, MI, and WMuta 
enrolled and managed patients, collected clinical data, and provided 
daily monitoring and supervision. SGha and EB managed and 
analysed the data. GPo and CS participated in training, clinical 
monitoring, and supervision, and writing the paper. UK and ET 
participated in study coordination, data interpretation, and writing of 
the report. VK participated in project coordination, supervision, and 
writing of the report.
Other contributors
Key clinical team members: Bruno Constant Mban, Petra Maagh, 
Sebastien Ngamitendi, Steve Harris, Alfred Luboya, Chief Mulowayi, 
Hilde Vochten, Jehu Moleko, Kathleen Thornberry, 
Katrien Timmermans, Omari Mwinyi, Patrice Kabangu, 
Didier Mukendi, Ismael Lumpungu, Phelinat Kalala Mbuyi.
Key laboratory ﬁ  eld team members: Albert Mpandzou, Ekofo Bolumbo, 
Espérant Bolimbo, Florence L’Huillier, Fréderic Maudoux, 
Isabelle Tilmant, Jean-Calvin Bay, Muriel Vincent, Zico Bwengo, 
Jeremy Ilunga, Jean Albert Kabulu, Betty Milomba, Michel Tshibasu, 
Marina Pozzoli.
Scientiﬁ  c committee for protocol development: Christian Burri, 
Cyrus Bacchi, Dominique Legros, François Chappuis, 
Marc Gastellu-Etchegorry, Philippe Büscher, Simon van Nieuwenhove.
Data and safety monitoring board: Pieter De Raadt, Jean Dupouy-Camet, 
Marleen Boelaert, Jacques Chandenier, Joris Menten.
Laboratory technical advice and training: Olivier Denis, Christian Kibonge, 
Barrie Rooney, Laurence Bonte, Philippe Büscher, Veerle Lejon, 
Nicolas Bebronne, Nathalie Nkoy.
Administrative and logistical support: Agnès Sobry, Angèle Ngo-on, 
Catherine Hamel, Davide Cantaluppi, Didier Dequatre, Françoise Saive, 
Ian Blake, Paul Foreman, Sylvaine Lonlas.
Advice on statistical matters: Loretxu Pinoges.
Advice on manuscript writing: Ann-Marie Sevcsik.
Conﬂ  icts of interest
We declare that we have no conﬂ  icts of interest.
Acknowledgments
The study was funded by the Dutch section of Médecins Sans Frontières 
and the Drugs for Neglected Diseases Initiative (DNDi). Médecins Sans 
Frontières International funded the original protocol development through 
the Nobel Prize Fund. DNDi would like to acknowledge the following 
donors for their support of DNDi’s NECT-related activities: the Department 
for International Development (DFID; UK), Médecins Sans Frontières 
International, the Medicor Foundation, the Ministry of Foreign and 
European Aﬀ  airs (France), and the Spanish Agency of International 
Cooperation for Development. The Médecins Sans Frontières Tritryps 
Working Group provided strategic and technical support throughout the Articles
64  www.thelancet.com   Vol 374   July 4, 2009
entire project. We thank the ministries of health of the Republic of the 
Congo and the Democratic Republic of the Congo, whose cooperation in 
setting up the study was invaluable. We acknowledge the clinical and 
laboratory ﬁ  eld team members, international and local, whose hard work 
allowed this research to be undertaken.
References
1  Simarro PP, Jannin J, Cattand P. Eliminating human African 
trypanosomiasis: where do we stand and what comes next? 
PLoS Med 2008; 5: e55.
2  WHO. Control and surveillance of African trypanosomiasis: report 
of a WHO Expert Committee. World Health Organ Tech Rep Ser 
1998; 881: 1–114.
3  Burri C, Keiser J. Pharmacokinetic investigations in patients from 
northern Angola refractory to melarsoprol treatment. 
Trop Med Int Health 2001; 6: 412–20.
4  Legros D, Evans S, Maiso F, Enyaru JC, Mbulamberi D. Risk factors 
for treatment failure after melarsoprol for Trypanosoma brucei 
gambiense trypanosomiasis in Uganda. Trans R Soc Trop Med Hyg 
1999; 93: 439–42.
5  Stanghellini A, Josenando T. The situation of sleeping sickness in 
Angola: a calamity. Trop Med Int Health 2001; 6: 330–34.
6  Robays J, Nyamowala G, Sese C, et al. High failure rates of 
melarsoprol for sleeping sickness, Democratic Republic of Congo. 
Emerg Infect Dis 2008; 14: 966–67.
7  Moore AC. Prospects for improving African trypanosomiasis 
chemotherapy. J Infect Dis 2005; 191: 1793–95.
8  Metcalf BW, Bey P, Danzin C, Jung MJ, Casara P, Vevert JP. 
Catalytic irreversible inhibition of mammalian ornithine 
decarboxylase (E.C.4.1.1.17) by substrate and product analogues. 
J Am Chem Soc 1978; 100: 2551–53.
9  Bacchi CJ, Nathan HC, Hutner SH, McCann PP, Sjoerdsma A. 
Polyamine metabolism: a potential therapeutic target in 
trypanosomes. Science 1980; 210: 332–34.
10  Bacchi CJ, Garofalo J, Mockenhaupt D, et al. In vivo eﬀ  ects of alpha-
DL-diﬂ  uoromethylornithine on the metabolism and morphology of 
Trypanosoma brucei brucei. Mol Biochem Parasitol 1983; 7: 209–25.
11 Abeloﬀ   MD, Slavik M, Luk GD, et al. Phase I trial and 
pharmacokinetic studies of alpha-diﬂ  uoromethylornithine—an 
inhibitor of polyamine biosynthesis. J Clin Oncol 1984; 2: 124–30.
12 Griﬃ   n CA, Slavik M, Chien SC, et al. Phase I trial and 
pharmacokinetic study of intravenous and oral alpha-
diﬂ  uoromethylornithine. Invest New Drugs 1987; 5: 177–86.
13  Pepin J, Khonde N, Maiso F, et al. Short-course eﬂ  ornithine in 
Gambian trypanosomiasis: a multicentre randomized controlled 
trial. Bull World Health Organ 2000; 78: 1284–95.
14  Janssens PG, De Muynck A. Clinical trials with “nifurtimox” in 
African trypanosomiasis. Ann Soc Belg Med Trop 1977; 57: 475–80.
15  Moens F, De Wilde M, Ngato K. Clinical trial of nifurtimox in 
human African trypanosomiasis. Ann Soc Belg Med Trop 1984; 
64: 37–43 (in French).
16  Pepin J, Milord F, Meurice F, Ethier L, Loko L, Mpia B. High-dose 
nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping 
sickness: an open trial in central Zaire. Trans R Soc Trop Med Hyg 
1992; 86: 254–56.
17  Van Nieuwenhove S. Advances in sleeping sickness therapy. 
Ann Soc Belg Med Trop 1992; 72 (suppl 1): 39–51.
18  Wegner DH, Rohwedder RW. The eﬀ  ect of nifurtimox in acute 
Chagas’ infection. Arzneimittelforschung 1972; 22: 1624–35.
19  Priotto G, Fogg C, Balasegaram M, et al. Three drug combinations for 
late-stage Trypanosoma brucei gambiense sleeping sickness: a 
randomized clinical trial in Uganda. PLoS Clin Trials 2006; 1: e39.
20  Checchi F, Piola P, Ayikoru H, Thomas F, Legros D, Priotto G. 
Nifurtimox plus eﬂ  ornithine for late-stage sleeping sickness in 
Uganda: a case series. PLoS Negl Trop Dis 2007; 1: e64.
21  Priotto G, Kasparian S, Ngouama D, et al. Nifurtimox-eﬂ  ornithine 
combination therapy for second-stage Trypanosoma brucei gambiense 
sleeping sickness: a randomized clinical trial in Congo. Clin Infect Dis 
2007; 45: 1435–42.
22  Burri C, Nkunku S, Merolle A, Smith T, Blum J, Brun R. Eﬃ   cacy of 
new, concise schedule for melarsoprol in treatment of sleeping 
sickness caused by Trypanosoma brucei gambiense: a randomised trial. 
Lancet 2000; 355: 1419–25.
23  Schmid C, Nkunku S, Merolle A, Vounatsou P, Burri C. Eﬃ   cacy of 
10-day melarsoprol schedule 2 years after treatment for late-stage 
gambiense sleeping sickness. Lancet 2004; 364: 789–90.
24  Bailey JW, Smith DH. The use of the acridine orange QBC technique 
in the diagnosis of African trypanosomiasis. Trans R Soc Trop Med Hyg 
1992; 86: 630.
25  WHO. Recommendations of the informal consultation on issues for 
clinical product development for human African trypanosomiasis. 
Geneva: World Health Organization, 2007. WHO/CDS/NTD/
IDM/2007.1. http://www.who.int/neglected_diseases/mediacentre/
Final%20Clinical_products_for_trypanosomiasis%20November%200
7.pdf (accessed June 9, 2009).
26  NCI-CTEP-NIH. Common toxicity criteria, version 2.0. Bethesda, 
MD: National Cancer Institute Cancer Therapy Evaluation Program, 
1999. http://ctep.info.nih.gov/protocolDevelopment/electronic_
applications/docs/ctcv20_4-30-992.pdf (accessed June 16, 2009).
27  Blackwelder WC. “Proving the null hypothesis” in clinical trials. 
Control Clin Trials 1982; 3: 345–53.
28  Iten M, Mett H, Evans A, Enyaru JC, Brun R, Kaminsky R. Alterations 
in ornithine decarboxylase characteristics account for tolerance of 
Trypanosoma brucei rhodesiense to D,L-alpha-diﬂ  uoromethylornithine. 
Antimicrob Agents Chemother 1997; 41: 1922–25.
29  Priotto G, Pinoges L, Fursa IB, et al. Safety and eﬀ  ectiveness of ﬁ  rst 
line eﬂ  ornithine for Trypanosoma brucei gambiense sleeping sickness 
in Sudan: cohort study. BMJ 2008; 336: 705–08.
30  Schmid C, Richer M, Bilenge CM, et al. Eﬀ  ectiveness of a 10-day 
melarsoprol schedule for the treatment of late-stage human African 
trypanosomiasis: conﬁ  rmation from a multinational study 
(IMPAMEL II). J Infect Dis 2005; 191: 1922–31.